---
title: "Design Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20, Implies 39% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286810211.md"
description: "Design Therapeutics, Inc. stock's 12-month price target has been raised to $20, indicating a 39% upside from the previous average of $19.33. Analysts' forecasts range from $15 to $22 per share. The consensus rating remains a 'Buy' with 7 analysts recommending buys and none holding or selling."
datetime: "2026-05-18T19:20:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286810211.md)
  - [en](https://longbridge.com/en/news/286810211.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286810211.md)
---

# Design Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20, Implies 39% Upside

-   According to estimates from 6 analysts, Design Therapeutics, Inc. stock's average price target has risen from $19.33 to $20, with forecasts ranging from $15 to $22 per share
-   Based on the May 15 closing price, the updated target implies approximately 39% potential upside
-   Consensus rating remains at “Buy” across 7 covering analysts, with 7 Buys, 0 Holds and 0 Sells

Explore more price target data and ratings for Design Therapeutics, Inc. on the , and track all previous and future analyst recommendations for Design Therapeutics, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [DSGN.US](https://longbridge.com/en/quote/DSGN.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results](https://longbridge.com/en/news/286141162.md)